This year, one of America’s favorite cereals saw its hopes to register its yellow box as a trademark crushed under the weight of the burden to prove acquired distinctiveness.
Qualitex Co. v. Jacobson Prods. Co. is…
In August, the USPTO issued Examination Guide 3-17, setting forth guidelines that effectively change the policies and procedures that address marks comprised of terms that are “primarily merely a surname” under §2(e)(4) of the Lanham…
- Trademarks Stuck in Limbo: The Genericness Trap
Imagine investing in brand identity and obtaining an incontestable registration for your mark. Imagine then having an identical, but stylized version of your mark refused by the USPTO for genericness in the span of just…
- USA Court of Appeals for the Federal Circuit Decision Concerning on Sale Bar in Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc.
Partner Sharon E. Crane authored a report, published by FICPI on August 23, 2017, titled "USA Court of Appeals for the Federal Circuit Decision Concerning on Sale Bar in Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc." The…
- FTC V. Qualcomm: The Balance Between Patents And Antitrust
Attorneys Derek F. Dahlgren and Spencer J. Johnson were featured in IP Law360’s Expert Analysis for their article entitled "FTC V. Qualcomm: The Balance Between Patents And Antitrust." To read the full article, please visit: https://www.law360.com/articles/956396.…
- View All Publications
BiosimilarsIP.com features articles, updates, and analysis on regulatory issues, legal decisions, and other news related to biologics and biosimilars under the Biologics Price Competition and Innovation Act (BPCIA). The posts, authored and edited by attorneys in the firm’s Biologics and Biosimilars practice group, track regulatory issues and events, provide analysis of legal decisions from federal courts and from the Patent Trial and Appeal Board, and offer updates on current news and events related to biologics and biosimilars. Our team understands the manufacturing, regulatory, and legal requirements of the field, and has the experience and the technical knowledge to handle the most sophisticated matters, including issues related to regulatory approval, securing patent rights, counseling and opinions, post-grant challenges, and asserting or defending against patents in litigation. To learn more, please visit www.BiosimilarsIP.com.Visit Blog
Authored and edited by attorneys in the firm’s Post-Grant Trial practice group, PTABLaw.com provides updates, articles, and analysis about the Patent Trial and Appeal Board (PTAB), the Court of Appeals for the Federal Circuit, and the American Invents Act. Our group has considerable experience handling inter partes review (IPR), covered business method (CBM) review, and post-grant review (PGR) proceedings before the PTAB. Our depth of knowledge and expertise with handling matters before the PTAB is unique, as many of the attorneys in our group have substantial experience in handling interference proceedings and reexaminations, and in prosecuting applications before the Office, as well as extensive litigation experience in the federal courts. To learn more, please visit www.PTABLaw.com.Visit Blog